Table 2 Analyses of OS in subgroups of patients with varying clinical characteristics

Aged < 65 years

Total

4

0.59

0.42–0.82

0.002

74%

0.009

monotherapy

2

0.78

0.65–0.93

0.005

24%

0.25

combination therapy

2

0.47

0.36–0.61

 < 0.00001

0%

0.51

Aged ≥ 65 years

Total

3

0.68

0.54–0.85

0.0008

0%

0.84

monotherapy

1

0.64

0.42–0.98

0.04

combination therapy

2

0.69

0.53–0.91

0.007

0%

0.60

Aged ≥ 75 years

Total

2

0.82

0.56–1.21

0.32

10%

0.29

monotherapy

2

0.82

0.56–1.21

0.32

10%

0.29

Male

Total

4

0.74

0.65–0.83

 < 0.00001

21%

0.28

monotherapy

2

0.68

0.46–1.00

0.05

71%

0.06

combination therapy

2

0.70

0.56–0.88

0.002

0%

0.95

Female

Total

4

0.57

0.31–1.06

0.08

87%

 < 0.0001

monotherapy

2

0.90

0.71–1.15

0.41

0%

0.83

combination therapy

2

0.32

0.23–0.46

 < 0.00001

0%

0.34

Squamous

Total

3

0.71

0.60–0.83

 < 0.0001

0%

0.71

monotherapy

2

0.74

0.61–0.92

0.005

0%

0.94

combination therapy

1

0.64

0.49–0.85

0.002

Non-squamous

Total

4

0.68

0.52–0.87

0.002

70%

0.02

monotherapy

2

0.73

0.50–1.07

0.10

73%

0.05

combination therapy

2

0.59

0.48–0.72

 < 0.00001

0%

0.36

PS 0

Total

4

0.67

0.54–0.83

0.0002

38%

0.18

monotherapy

2

0.78

0.61–1.01

0.06

0%

0.97

combination therapy

2

0.48

0.33–0.69

0.0001

0%

0.63

PS 1

Total

4

0.66

0.52–0.83

0.0005

66%

0.03

monotherapy

2

0.71

0.48–1.04

0.08

73%

0.05

combination therapy

2

0.59

0.47–0.74

 < 0.00001

0%

0.36

Active or previous smoker

Total

3

0.65

0.52–0.82

0.0003

51%

0.13

monotherapy

2

0.72

0.59–0.88

0.002

24%

0.25

combination therapy

1

0.54

0.41–0.71

 < 0.0001

Never smoker

Total

3

0.57

0.18–1.80

0.34

80%

0.007

monotherapy

2

1.00

0.73–1.36

0.99

0%

0.92

combination therapy

1

0.23

0.10–0.54

0.0007

With brain metastasis

Total

2

0.44

0.27–0.70

0.0006

0%

0.40

monotherapy

1

0.73

0.20–2.62

0.63

combination therapy

1

0.41

0.24–0.67

0.0005

Without brain metastasis

Total

2

0.60

0.50–0.73

 < 0.00001

0%

0.70

monotherapy

1

0.64

0.46–0.88

0.006

combination therapy

1

0.59

0.46–0.75

 < 0.0001

PD-L1 tumor proportion score < 1%

Total

2

0.55

0.41–0.73

 < 0.0001

0%

0.58

combination therapy

2

0.55

0.41–0.73

 < 0.0001

0%

0.58

PD-L1 tumor proportion score ≥ 1%

Total

3

0.71

0.58–0.87

0.001

53%

0.12

monotherapy

1

0.81

0.71–0.93

0.003

combination therapy

2

0.62

0.50–0.77

 < 0.0001

0%

0.78

PD-L1 tumor proportion score 1–49%

Total

3

0.72

0.52–1.01

0.06

67%

0.05

monotherapy

1

0.92

0.77–1.11

0.40

combination therapy

2

0.60

0.44–0.81

0.0007

0%

0.77

PD-L1 tumor proportion score ≥ 50%

Total

4

0.66

0.56–0.76

 < 0.00001

0%

0.90

monotherapy

2

0.67

0.57–0.80

 < 0.00001

0%

0.66

combination therapy

2

0.60

0.44–0.84

0.002

0%

0.81